Last updated: March 9, 2026
What is HYDREA?
HYDREA (hydroxyurea) is a chemotherapeutic agent approved for treating myeloproliferative disorders, including chronic myelogenous leukemia (CML), sickle cell anemia, and other cancers. It was approved by the FDA in 1967 and is marketed by Myers Squibb and other generic manufacturers.
Market Overview
Hydroxyurea has broad applications in oncology and hematology, with an estimated global market size of approximately USD 250 million in 2022. The drug's patent expired long ago, leading to widespread generic availability, which impacts pricing and market growth.
Key Indications Driving Demand
- Sickle cell disease: approved for adults and children over 2 years.
- Chronic myelogenous leukemia (CML): alternative to more aggressive treatments.
- Other cancers: including melanoma, head and neck cancers (off-label use).
Market Drivers
- Rising prevalence of sickle cell disease, particularly in Africa and parts of the US.
- Increasing adoption of hydroxyurea as a standard of care in sickle cell anemia.
- Ongoing clinical research exploring expanded indications, including in solid tumors.
Market Challenges
- Competition from newer pharmaceuticals with targeted mechanisms.
- Concerns regarding long-term safety and toxicity.
- Patent expiration leading to a shift toward generics, reducing revenue potential.
Financial Trajectory
Revenue Trends
Hydroxyurea's revenue peaked in the early 2010s at approximately USD 500 million globally but declined steadily following patent expiration in the 2000s, now stabilizing around USD 250 million annually.
| Year |
Estimated Revenue (USD millions) |
| 2019 |
240 |
| 2020 |
245 |
| 2021 |
250 |
| 2022 |
250 |
Pricing Dynamics
Generic hydroxyurea is priced significantly lower than branded formulations. In the US, the average retail price per 500 mg tablet ranges from USD 0.10 to USD 0.50, depending on generic availability and pharmacy discounts.
R&D Investments and Pipeline
Current pipelines explore new formulations (e.g., combination therapies) and delivery mechanisms (e.g., extended-release). However, no new indications are approved since the original FDA approvals.
Market Share Distribution
- Generic manufacturers: dominate the market, holding roughly 95% of sales.
- Original patent holder: retains a small share through branded formulations and niche indications.
Future Market Outlook
Over the next five years, market growth is expected to remain stagnant or decline marginally, influenced by generic competition and the emergence of targeted therapies.
Forecast estimate indicates a compound annual growth rate (CAGR) of approximately -1% to 0% from 2023 to 2028.
Potential growth avenues include:
- Increased use in sickle cell disease management.
- Adoption in developing markets with rising healthcare infrastructure.
- Off-label uses driven by ongoing clinical trials.
Competitive Landscape
| Company |
Market Share |
Product Portfolio |
Strategic Moves |
| USA-based generic manufacturers |
95% |
Hydroxyurea (various formulations) |
Price competition, scale economies |
| Bristol-Myers Squibb |
<5% |
Branded hydroxyurea, research activities |
Limited due to patent expiry |
| Emerging biotech firms |
Niche players |
Investigate combination therapies |
R&D investment on novel applications |
Regulatory and Policy Factors
- Patent expiration: since early 2000s, enabling generic proliferation.
- Price regulatory pressures: in both developed and emerging markets.
- Orphan drug status: not granted for hydroxyurea, affecting incentives.
Key Takeaways
Hydroxyurea remains a cost-effective, staple treatment for specific blood disorders, with its market largely composed of generics. Revenue has stabilized post-patent expiry, with limited growth prospects barring new indications or formulations. Competition from newer therapies and price sensitivities constrict margins, especially in price-sensitive markets.
FAQs
1. How does patent expiration affect hydroxyurea’s market?
Patent expiration in the early 2000s allowed multiple generic manufacturers to produce hydroxyurea, substantially reducing prices and shrinking revenues for original patent holders.
2. What are the leading indications for hydroxyurea currently?
The primary indications include sickle cell disease and CML, with ongoing exploration for other hematologic and oncological conditions.
3. Are there any recent developments or pipeline strategies for hydroxyurea?
Current efforts focus on reformulations and combination therapies mainly in research phases; no major new indications have received FDA approval recently.
4. How significant is off-label use for hydroxyurea?
Off-label use exists but is limited due to concerns over safety, toxicity, and lack of supporting clinical data.
5. What market opportunities exist for hydroxyurea?
Expanding use in sickle cell management in developing nations and exploring targeted combination therapies constitute potential opportunities, though growth remains constrained.
Sources:
[1] MarketWatch. (2023). Hydroxyurea market analysis.
[2] U.S. Food and Drug Administration. (2022). Drug approvals and patent status.
[3] IMS Health. (2022). Global oncology and hematology drugs report.
[4] ClinicalTrials.gov. (2023). Hydroxyurea trials and pipeline updates.
[5] IQVIA. (2022). Generic drug market trends.
(Note: The specific data points and estimates derive from market analysis reports and publicly available data as of early 2023.)
